CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that it has entered into a partnership agreement with Kawasumi Laboratories to develop an INTERCEPT platelet kit designed for use in Japan.
“We are delighted to enter into this important partnership with Kawasumi Laboratories,” said William ‘Obi’ Greenman, Cerus’ chief executive officer and president. “By leveraging Kawasumi’s global manufacturing expertise and unique position in the Japanese market, we will be able to propose to the Japanese Red Cross a version of the INTERCEPT Blood System for platelets that is optimized for Japan’s blood products specifications, with kits meeting the highest quality standards.”
Help employers find you! Check out all the jobs and post your resume.
